^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 765049

    i
    Other names: BI 765049, B7-H6/CD3 T-cell engager, OBT624, BI765049, OBT 624, BI-765049, OBT-624
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim, Oxford BioTherap
    Drug class:
    CD3 agonist, B7-H6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=70, Recruiting, Boehringer Ingelheim | Trial completion date: Dec 2027 --> Sep 2028 | Trial primary completion date: Sep 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    3ms
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=70, Recruiting, Boehringer Ingelheim | Trial completion date: Feb 2027 --> Dec 2027 | Trial primary completion date: Nov 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    6ms
    A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas (clinicaltrials.gov)
    P1, N=135, Recruiting, Boehringer Ingelheim | N=100 --> 135
    Enrollment change
    |
    BI 765049
    8ms
    A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas (clinicaltrials.gov)
    P1, N=100, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BI 765049
    9ms
    A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Boehringer Ingelheim
    New P1 trial
    |
    BI 765049
    11ms
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface (clinicaltrials.gov)
    P1, N=67, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed | Trial completion date: Dec 2028 --> Nov 2024 | Trial primary completion date: Dec 2025 --> Nov 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    1year
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface (clinicaltrials.gov)
    P1, N=67, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | N=248 --> 67
    Enrollment closed • Enrollment change • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    over1year
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface (clinicaltrials.gov)
    P1, N=248, Recruiting, Boehringer Ingelheim | N=120 --> 248
    Enrollment change • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    almost2years
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Having the B7-H6 Marker (clinicaltrials.gov)
    P1, N=120, Recruiting, Boehringer Ingelheim | Trial completion date: May 2025 --> Dec 2028 | Trial primary completion date: May 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    almost2years
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=70, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    2years
    A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Having the B7-H6 Marker (clinicaltrials.gov)
    P1, N=120, Recruiting, Boehringer Ingelheim | Trial primary completion date: Nov 2023 --> May 2025
    Trial primary completion date
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049
    2years
    A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6 (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Boehringer Ingelheim | Trial completion date: Jan 2026 --> Mar 2027 | Trial primary completion date: Nov 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1)
    |
    ezabenlimab (BI 754091) • BI 765049